BerGenBio ASA (BGBIO.OL)

NOK 8.72

(-2.83%)

Net Income Summary of BerGenBio ASA

BerGenBio ASA's latest annual net income in 2023 was -190.4 Million NOK , up 36.24% from previous year.
BerGenBio ASA's latest quarterly net income in 2024 Q2 was -49.72 Million NOK , down -37.66% from previous quarter.
BerGenBio ASA reported an annual net income of -298.6 Million NOK in 2022, up 3.49% from previous year.
BerGenBio ASA reported an annual net income of -309.41 Million NOK in 2021, down -20.37% from previous year.
BerGenBio ASA reported a quarterly net income of -49.72 Million NOK for 2024 Q2, down -37.66% from previous quarter.
BerGenBio ASA reported a quarterly net income of -27.93 Million NOK for 2023 Q3, up 42.8% from previous quarter.

Annual Net Income Chart of BerGenBio ASA (2023 - 2014)

Historical Annual Net Income of BerGenBio ASA (2023 - 2014)

Year	Net Income	Net Income Growth
2023	-190.4 Million NOK	36.24%
2022	-298.6 Million NOK	3.49%
2021	-309.41 Million NOK	-20.37%
2020	-257.06 Million NOK	-28.93%
2019	-199.38 Million NOK	-3.98%
2018	-191.74 Million NOK	-5.24%
2017	-182.2 Million NOK	-40.38%
2016	-129.79 Million NOK	-80.01%
2015	-72.1 Million NOK	-24.8%
2014	-57.78 Million NOK	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-36.11 Million NOK	13.26%
2024 Q2	-49.72 Million NOK	-37.66%
2023 Q3	-27.93 Million NOK	42.8%
2023 Q2	-48.83 Million NOK	31.77%
2023 FY	-190.4 Million NOK	36.24%
2023 Q1	-71.57 Million NOK	8.21%
2023 Q4	-41.63 Million NOK	-49.06%
2022 Q1	-83.56 Million NOK	-21.53%
2022 FY	-298.6 Million NOK	3.49%
2022 Q4	-77.97 Million NOK	-36.4%
2022 Q3	-57.16 Million NOK	28.45%
2022 Q2	-79.9 Million NOK	4.39%
2021 Q2	-88.85 Million NOK	-9.37%
2021 Q3	-70.49 Million NOK	20.66%
2021 Q4	-68.76 Million NOK	2.46%
2021 Q1	-81.24 Million NOK	-9.99%
2021 FY	-309.41 Million NOK	-20.37%
2020 Q3	-67.32 Million NOK	-0.07%
2020 Q4	-73.86 Million NOK	-9.72%
2020 FY	-257.06 Million NOK	-28.93%
2020 Q1	-48.56 Million NOK	15.67%
2020 Q2	-67.27 Million NOK	-38.53%
2019 Q3	-44.59 Million NOK	15.52%
2019 FY	-199.38 Million NOK	-3.98%
2019 Q4	-57.58 Million NOK	-29.14%
2019 Q2	-52.78 Million NOK	-19.13%
2019 Q1	-44.31 Million NOK	13.24%
2018 Q3	-37.65 Million NOK	23.52%
2018 Q4	-51.07 Million NOK	-35.63%
2018 Q2	-49.23 Million NOK	8.45%
2018 FY	-191.74 Million NOK	-5.24%
2018 Q1	-53.78 Million NOK	-12.9%
2017 Q2	-34.08 Million NOK	47.62%
2017 Q1	-65.06 Million NOK	-133.21%
2017 FY	-182.2 Million NOK	-40.38%
2017 Q3	-35.42 Million NOK	-3.94%
2017 Q4	-47.63 Million NOK	-34.46%
2016 FY	-129.79 Million NOK	-80.01%
2016 Q3	-15.37 Million NOK	76.77%
2016 Q2	-66.2 Million NOK	0.0%
2016 Q4	-27.9 Million NOK	-81.44%
2015 FY	-72.1 Million NOK	-24.8%
2014 FY	-57.78 Million NOK	0.0%

Peer Net Income Comparison of BerGenBio ASA

Name	Net Income	Net Income Difference
Arctic Bioscience AS	-45.51 Million NOK	-318.329%
Aqua Bio Technology ASA	-19.11 Million NOK	-896.198%
ArcticZymes Technologies ASA	19.42 Million NOK	1080.185%
Hofseth BioCare ASA	-106.68 Million NOK	-78.474%
PCI Biotech Holding ASA	-20.31 Million NOK	-837.243%
Thor Medical ASA	-26.56 Million NOK	-616.844%
Ultimovacs ASA	-189.23 Million NOK	-0.614%